Announcements Trials
Browse Landscape

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 36Observational 5Expanded_access 2

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 4ALK-positive NSCLC 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Crizotinib × Clear all
NCT03375242 2026-03-30

Safety and Efficacy of Xalkori ROS1

Pfizer

Active not recruiting
97 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Pfizer

Completed
5,279 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Pfizer

Completed
692 enrolled 25 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

NCT01597258 2019-09-13

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Pfizer

Completed
2,029 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡